Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 136, Issue 9, 2002, Pages 680-690

  Miller, Jill ^a   Chan, Benjamin K S ^a   Nelson, Heidi D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

BAYES THEOREM; COCHRANE LIBRARY; ESTROGEN THERAPY; HEALTH HAZARD; HUMAN; MEDLINE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; UNITED STATES;

EID: 0037035553     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-9-200205070-00011     Document Type: Review

References (45)

1. Use of hormone replacement therapy by postmenopausal women in the United States
2. Oral contraceptives and venous thromboembolism: Findings in a large prospective study
3. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center
4. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors
5. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
6. Risk of venous thromboembolism in users of hormone replacement therapy
7. Case-control study of venous thromboembolism risk in users of hormone replacement therapy
8. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
9. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
10. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe
11. Prospective study of exogenous hormones and risk of pulmonary embolism in women
12. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
13. Hormone replacement therapy with estradiol and risk of venous thromboembolism - A population-based case-control study
14. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
15. Hormone replacement therapy and cognition: Systematic review and meta-analysis
16. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
17. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
18. Estrogen replacement therapy and the risk of venous thrombosis
19. Bias in meta-analysis detected by a simple, graphical test
20. A nonparametric "trim fill" method of accounting for publication bias in meta-analysis
21. Empirical assessment of effect of publication bias on meta-analyses
22. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease
23. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin replacement study
24. Findings leading to discontinuation of the 2.5-mg day estrogen group
25. Early risks of hormone therapy in patients with coronary heart disease
26. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
27. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
28. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
29. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
30. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
31. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative
32. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
33. Postmenopausal female hormone use and venous thromboembolic disease in black women
34. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
35. Actions of oestrogen on vascular endothelial and smooth-muscle cells
36. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women
37. Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy
38. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study
39. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)
40. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C)
41. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy